Coumarin‐containing hybrids and their antibacterial activities

Authors:
Publisher website
Google Scholar
Abstract
Infections caused by Gram‐positive and ‐negative bacteria are one of the foremost causes of morbidity and mortality globally. Antibiotics are the mainstay of therapy for bacterial infections, but the emergence and wide spread of drug‐resistant pathogens have already become a huge issue for public healthcare systems. The coumarin moiety, which is ubiquitous in nature, could bind to the B subunit of DNA gyrase in bacteria and inhibit DNA supercoiling by blocking the ATPase activity; hence, coumarin derivatives possess potential antibacterial activity. Several coumarin‐containing hybrids such as coumermycin A1, clorobiocin, and novobiocin have already been used in clinical practice for the treatment of various bacterial infections; thus, it is conceivable that hybridization of the coumarin moiety with other antibacterial pharmacophores may provide opportunities for the development of novel antibiotics. This review outlines the advances in coumarin‐containing hybrids with antibacterial potential in the recent 5 years and the structure–activity relationships are also discussed.
Funding Information
  • Research and Innovation Team of Hunan University of Medicine (2019-48)
  • Natural Science Foundations of China (U1812403)

This publication has 122 references indexed in Scilit: